Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class issued on 1 August 2016, PHARMAC has entered into a provisional agreement with Pfizer.
PHARMAC is seeking feedback on a proposal to:
- list celecoxib 100 mg and 200 mg capsules from 1 June 2017 in Section B and Part II of Section H (Hospital Medicines List) of the Pharmaceutical Schedule with no restrictions.
- award Sole Supply Status and Hospital Supply Status to Pfizer’s brand of celecoxib (Celecoxib Pfizer) from 1 August 2017 until 30 June 2020.
- delist all other oral selective COX-2 inhibitor presentations of the ‘coxib’ class (all strengths of etoricoxib tablets and celecoxib 400 mg tablets) from the Hospital Medicines List from 1 August 2017.
